Heart failure & cardiomyopathiesSecondary analysis
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial
- Prespecified secondary analysis of the FINEARTS-HF randomised trial
- placebo-controlled
- prespecified analysis by left ventricular ejection fraction (LVEF)
Authors' conclusion
In patients with HF with mildly reduced or preserved ejection fraction, finerenone reduced the risk of cardiovascular death and worsening HF events, irrespective of LVEF.
Study context
- Population
- Patients with heart failure (HF) and LVEF ≥40% (mildly reduced or preserved EF)LVEF available for 5993
- Participants
- 6,001 patients
- Comparison
- Finerenone vs placebo, by LVEF
- Primary endpoint
- Composite of:
- Total (first and recurrent) worsening HF events
- CV death
Primary result
As reported in the abstract
CV death and total worsening HF events, by LVEF category
Finerenone vs PlaceboRate ratio (95% CI)
LVEF <50% (n = 2172)
0.84(0.68–1.03)
LVEF ≥50% to <60% (n = 2674)
0.80(0.66–0.97)
LVEF ≥60% (n = 1147)
0.94(0.70–1.25)
- No modification of benefit across LVEF as a continuous variable
- P for interaction = 0.28
Further findings
Total worsening HF events, by LVEF
- Similar consistent effect of finerenone across LVEF
- continuous Pinteraction=0.26
Baseline LVEF
- Mean LVEF
- 53±8%
- Median LVEF (IQR 46%-58%)
- 53%
Original publication
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Circulation. Published 29 September 2024. doi:10.1161/circulationaha.124.072011
Summarised from the published abstract; every number is checked against it